Nicholas M Barbaro1, Mark Quigg2, Mariann M Ward3, Edward F Chang3, Donna K Broshek4, John T Langfitt5, Guofen Yan6, Kenneth D Laxer7, Andrew J Cole8, Penny K Sneed9, Christopher P Hess10, Wei Yu6, Manjari Tripathi11, Christianne N Heck12, John W Miller13, Paul A Garcia14, Andrew McEvoy15, Nathan B Fountain2, Vincenta Salanova16, Robert C Knowlton14, Anto Bagić17, Thomas Henry18, Siddharth Kapoor19, Guy McKhann20, Adriana E Palade21, Markus Reuber22, Evelyn Tecoma23. 1. Department of Neurological Surgery, Indiana University, Indianapolis, IN, USA. 2. Department of Neurology, University of Virginia, Charlottesville, VA, USA. 3. Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA. 4. Department of Psychiatry, University of Virginia, Charlottesville, VA, USA. 5. Department of Neurology, University of Rochester, Rochester, NY, USA. 6. Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA. 7. Department of Neurology, California Pacific Medical Center, San Francisco, CA, USA. 8. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. 9. Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA. 10. Department of Radiology, University of California San Francisco, San Francisco, CA, USA. 11. Department of Neurology, All India Institute of Medical Science, New Delhi, India. 12. Department of Neurology, University of Southern California, Los Angeles, CA, USA. 13. Department of Neurology, University of Washington, Seattle, WA, USA. 14. Department of Neurology, University of California San Francisco, San Francisco, CA, USA. 15. Department of Clinical and Experimental Epilepsy, University College London, London, UK. 16. Department of Neurology, Indiana University, Indianapolis, IN, USA. 17. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA. 18. Department of Neurology, University of Minnesota, Minneapolis, MN, USA. 19. Department of Neurology, University of Kentucky, Lexington, KY, USA. 20. Department of Neurosurgery, Columbia University, New York, NY, USA. 21. Department of Neurology, University of Louisville, Louisville, KY, USA. 22. Department of Neuroscience, University of Sheffield, Sheffield, UK. 23. Department of Neurology, University of California San Diego, San Diego, CA, USA.
Abstract
OBJECTIVE: To compare stereotactic radiosurgery (SRS) versus anterior temporal lobectomy (ATL) for patients with pharmacoresistant unilateral mesial temporal lobe epilepsy (MTLE). METHODS: This randomized, single-blinded, controlled trial recruited adults eligible for open surgery among 14 centers in the USA, UK, and India. Treatment was either SRS at 24 Gy to the 50% isodose targeting mesial structures, or standardized ATL. Outcomes were seizure remission (absence of disabling seizures between 25 and 36 months), verbal memory (VM), and quality of life (QOL) at 36-month follow-up. RESULTS: A total of 58 patients (31 in SRS, 27 in ATL) were treated. Sixteen (52%) SRS and 21 (78%) ATL patients achieved seizure remission (difference between ATL and SRS = 26%, upper 1-sided 95% confidence interval = 46%, P value at the 15% noninferiority margin = .82). Mean VM changes from baseline for 21 English-speaking, dominant-hemisphere patients did not differ between groups; consistent worsening occurred in 36% of SRS and 57% of ATL patients. QOL improved with seizure remission. Adverse events were anticipated cerebral edema and related symptoms for some SRS patients, and cerebritis, subdural hematoma, and others for ATL patients. SIGNIFICANCE: These data suggest that ATL has an advantage over SRS in terms of proportion of seizure remission, and both SRS and ATL appear to have effectiveness and reasonable safety as treatments for MTLE. SRS is an alternative to ATL for patients with contraindications for or with reluctance to undergo open surgery. Wiley Periodicals, Inc.
RCT Entities:
OBJECTIVE: To compare stereotactic radiosurgery (SRS) versus anterior temporal lobectomy (ATL) for patients with pharmacoresistant unilateral mesial temporal lobe epilepsy (MTLE). METHODS: This randomized, single-blinded, controlled trial recruited adults eligible for open surgery among 14 centers in the USA, UK, and India. Treatment was either SRS at 24 Gy to the 50% isodose targeting mesial structures, or standardized ATL. Outcomes were seizure remission (absence of disabling seizures between 25 and 36 months), verbal memory (VM), and quality of life (QOL) at 36-month follow-up. RESULTS: A total of 58 patients (31 in SRS, 27 in ATL) were treated. Sixteen (52%) SRS and 21 (78%) ATL patients achieved seizure remission (difference between ATL and SRS = 26%, upper 1-sided 95% confidence interval = 46%, P value at the 15% noninferiority margin = .82). Mean VM changes from baseline for 21 English-speaking, dominant-hemisphere patients did not differ between groups; consistent worsening occurred in 36% of SRS and 57% of ATL patients. QOL improved with seizure remission. Adverse events were anticipated cerebral edema and related symptoms for some SRSpatients, and cerebritis, subdural hematoma, and others for ATL patients. SIGNIFICANCE: These data suggest that ATL has an advantage over SRS in terms of proportion of seizure remission, and both SRS and ATL appear to have effectiveness and reasonable safety as treatments for MTLE. SRS is an alternative to ATL for patients with contraindications for or with reluctance to undergo open surgery. Wiley Periodicals, Inc.
Authors: John P Andrews; Abhijeet Gummadavelli; Pue Farooque; Jennifer Bonito; Christopher Arencibia; Hal Blumenfeld; Dennis D Spencer Journal: JAMA Neurol Date: 2019-04-01 Impact factor: 18.302
Authors: Siobhan West; Sarah J Nevitt; Jennifer Cotton; Sacha Gandhi; Jennifer Weston; Ajay Sudan; Roberto Ramirez; Richard Newton Journal: Cochrane Database Syst Rev Date: 2019-06-25
Authors: Jon T Willie; James G Malcolm; Matthew A Stern; Lindsay O Lowder; Stewart G Neill; Brian T Cabaniss; Daniel L Drane; Robert E Gross Journal: Epilepsia Date: 2019-01-17 Impact factor: 5.864
Authors: Kajol Marathe; Ali Alim-Marvasti; Karan Dahele; Fenglai Xiao; Sarah Buck; Aidan G O'Keeffe; John S Duncan; Vejay N Vakharia Journal: Front Neurol Date: 2021-12-09 Impact factor: 4.003